What Researchers Did
Researchers reviewed the current understanding and application of hyperbaric oxygen therapy (HBOT) for the treatment of wounds.
What They Found
They found that hyperbaric oxygen therapy (HBOT) is a Medicare-approved treatment for several conditions, including chronic nonhealing wounds and radiation necrosis. HBOT works by using high pressures to saturate hemoglobin and dissolve oxygen into blood plasma, creating a hyperoxemic environment to reverse tissue injury. However, HBOT is expensive and carries risks, necessitating adequate treatment of the underlying etiology before its use as an adjunct therapy.
What This Means for Canadian Patients
Canadian patients with chronic nonhealing wounds may consider hyperbaric oxygen therapy (HBOT) as a potential adjunct treatment option. However, given its cost and risks, it is crucial that the underlying cause of the wound is addressed first to maximize the therapy's benefits.
Canadian Relevance
This review does not specifically address Canadian healthcare contexts or patient populations.
Study Limitations
As a review, this study synthesizes existing literature but does not present new empirical data or specific quantitative outcomes regarding HBOT efficacy or cost.